Relaxation of human pulmonary arteries by PPARγ agonists by Hanna Kozłowska et al.
ORIGINAL ARTICLE
Relaxation of human pulmonary arteries by PPARγ agonists
Hanna Kozłowska & Marta Baranowska-Kuczko &
Eberhard Schlicker & Mirosław Kozłowski &
Monika Kloza & Barbara Malinowska
Received: 31 October 2012 /Accepted: 28 February 2013 /Published online: 13 March 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract It has been suggested that activation of nuclear
peroxisome proliferator-activated receptors γ (PPARγ) may
represent a new strategy for the treatment of pulmonary arterial
hypertension. It has been demonstrated that PPARγ activation
relaxed the isolated mouse pulmonary artery. The aims of the
present study were to examine whether and to which extent the
two PPARγ agonists rosiglitazone and pioglitazone relax the
isolated human pulmonary artery and to investigate the under-
lying mechanism(s). Isolated human pulmonary arteries were
obtained from patients without clinical evidence of pulmonary
hypertension during resection of lung carcinoma. Vasodilatory
effects of PPARγ agonists were examined on endothelium-
intact or endothelium-denuded vessels preconstricted with
the thromboxane prostanoid receptor agonist U-46619.
Rosiglitazone and pioglitazone (0.01–100 μM) caused a
concentration- and/or time-dependent full relaxation of U-
46619-preconstricted vessels. The rosiglitazone-induced re-
laxation was attenuated by the PPARγ antagonist GW9662
1 μM, endothelium denudation, the nitric oxide synthase
inhibitor L-NAME 300 μM, the cyclooxygenase inhibitor
indomethacin 10 μM, and the KATP channel blocker
glibenclamide 10 μM. The prostacyclin IP receptor antagonist
RO1138452 1 μM shifted the concentration–response curve
for rosiglitazone to the right. The PPARγ agonists pioglitazone
and rosiglitazone relax human pulmonary arteries. The
rosiglitazone-induced vasorelaxation is partially endothelium-
dependent and involves PPARγ receptors, arachidonic acid
degradation products, nitric oxide, and KATP channels. Thus,
the relaxant effect of PPARγ agonists in human pulmonary
arteries may represent a new therapeutic target in pulmonary
arterial hypertension.
Keywords Humanpulmonary artery .KATP channels .Nitric
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Introduction
Pulmonary arterial hypertension (PAH) is a disease charac-
terized by increased pulmonary arterial pressure accompa-
nied by an increase in pulmonary vascular resistance, by
pulmonary vascular remodeling, and endothelial dysfunc-
tion leading to right ventricular failure and premature death.
So far, the available therapies (including phosphodiesterase
type 5 inhibitors, endothelin-1 receptor antagonists or pros-
tacyclin mimetics) may help relieve symptoms and slow the
progress of the disease but still PAH has no cure. Thus, there
is an urgent need for novel and more effective therapeutic
strategies in the PAH treatment. In recent years, evidence
has been accumulating that activation of nuclear peroxisome
proliferator-activated receptors γ (PPARγ) may be a novel,
attractive PAH therapeutic target (for review, see, e.g., Sutliff
et al. 2010; Archer et al. 2010; Green et al. 2011).
PPARγ receptors are normally expressed in human en-
dothelial and smooth muscle cells of the pulmonary vascular
wall (for review, see, e.g., Sutliff et al. 2010; Green et al.
2011). However, their expression was diminished in vascu-
lar lesions (both in smooth muscle and endothelial cells)
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from patients with primary and secondary pulmonary hyper-
tension (Ameshima et al. 2003). Moreover, hypoxia decreased
PPARγ expression in human pulmonary artery smooth mus-
cle and endothelial cells (Lu et al. 2010; Nisbet et al. 2010).
The above observations are further supported by experiments
on animals. Thus, hypoxia induced severe PAH and decreased
lung vascular PPARγ expression in mice (Gong et al. 2011)
and in rats (Ameshima et al. 2003; Kim et al. 2010; Gong et al.
2011). Similarly, the PPARγ protein level in lung tissue was
also diminished in a lamb model of increased pulmonary
blood flow and PAH induced by an aorta-to-pulmonary artery
shunt (Oishi et al. 2013).
From all PPARγ ligands, thiazolidinediones are of the most
clinical importance. They are insulin sensitizers and are known
because of their antidiabetic efficacy. Increasing evidence sug-
gests that thiazolidinediones, in addition to improving glyce-
mic control, cause vascular vasodilatation of systemic arteries
and modestly lower blood pressure both in human and in
animal insulin-resistant and non-insulin-resistant models of
hypertension (for review, see, e.g., Sigmund 2010; Sutliff et
al. 2010; Green et al. 2011; Salomone and Drago 2012). The
representative members of thiazolidinediones and PPARγ ag-
onists are rosiglitazone and pioglitazone. Rosiglitazone is one
of the most potent and selective synthetic agonists of PPARγ
receptors, and pioglitazone is the only thiazolidinedione
currently approved for clinical practice in Europe (for reviews,
see Michalik et al. 2006; Ciudin et al. 2012). Unfortunately,
their effects on pulmonary circulation have been examined in
few studies only. So, chronic rosiglitazone administration
prevented the loss of agonist-induced endothelium-dependent
vascular relaxation in the lamb model mentioned above (Oishi
et al. 2013). It also attenuated the hypoxia-induced PAH in rats
(Crossno et al. 2007; Kim et al. 2010) and in adult (but not in
newborn) mice (Nisbet et al. 2010; Nicola et al. 2011).
Moreover, it prevented PAH development in male apolipopro-
tein E-deficient (ApoE−/−) mice on a high-fat diet (Hansmann
et al. 2007).
In other words, PPARγ agonists protect against PAH
development in a series of experimental models and their
beneficial effects may be connected, e.g., with the alter-
ation of the balance between vasoconstrictor and vasodi-
lator substances (for review, see Sutliff et al. 2010; Green
et al. 2011; Salomone and Drago 2012). A direct
vasodilatory effect of rosiglitazone in the isolated pulmo-
nary artery has been so far shown in the mouse only
(Harrington et al. 2010). Thus, the aim of the present study
was to examine the vasodilator effect of rosiglitazone
also in the human pulmonary artery (hPA) and to include
pioglitazone, another representative member of PPARγ ago-
nists. In addition, the involvement of PPARγ receptors, endo-
thelium, arachidonic acid degradation products, nitric oxide,
and KATP channels in the vasodilator effect of rosiglitazone
was investigated.
Material and methods
In accordance with the Declaration of Helsinki, the study
protocol was approved by the local ethics committee (No.
R-I-002/309/2008), and written informed consent was
obtained from all donors for the use of their tissue.
Tissue preparation
Human lung tissue was obtained from 44 patients (31 men and
13 women, mean age 66.5±1.9 years) undergoing lobectomy
or pneumonectomy during resection of lung carcinoma.
Preoperative echocardiography revealed normal left and right
ventricular function in each case. Patients did not have any
clinical evidence of pulmonary hypertension nor did they
receive beta-blockers. Before the operation, all patients re-
ceived cephalosporins and low molecular weight heparin as
anti-infection and anti-thrombotic prophylaxis, respectively.
The tissue was transported to the laboratory within half an
hour in cold (4 °C), pre-gassed Tyrode’s bicarbonate solution
(for composition, see below). Lobar and segmental branches
of the hPA were cleaned from the lung parenchyma and cut
into rings (from the middle portion of each artery; 3–5 mm
length and 2–4 mm outer diameter).
Organ bath technique
The arterial rings were suspended on stainless steel wires in
10 ml organ baths containing Tyrode’s solution (concentra-
tion in mM: NaCl, 139.2; KCl, 2.7; CaCl2, 1.8; MgCl2,
0.49; NaHCO3, 11.9; NaH2PO4, 0.4; glucose, 5.5) and were
gassed continuously with 95 % O2 and 5 % CO2, at 37 °C
and pH7.4. Pulmonary artery rings were allowed to equili-
brate for 90 min; during this time period, the bath fluid was
exchanged every 10 min with fresh Tyrode’s solution. The
optimal resting tension was about 20–25 mN (depending on
the rings’ internal diameter), which ensured that responses
to agonists were maximal. Muscle tension was recorded by a
force displacement transducer (PIM 100RE, BIO-SYS-
TECH, Białystok, Poland) and displayed on a computer.
After the equilibration period, all rings were preconstricted
submaximally with phenylephrine (1 μM) to prime the tissues
and to check the functionality of the endothelium (at least
80 % relaxation in response to acetylcholine 1 μM). For
experiments with endothelium-free vascular wall, vessels
were denuded by rubbing the intimal surface mechanically,
and successful endothelial removal was confirmed by a lack of
vasorelaxant response to acetylcholine. Viable vessels were
constricted submaximally with U-46619 (a thromboxane
prostanoid receptor agonist). Since the degree of relaxation
crucially depends on the level of the tone of the tissue
(Guimarães and Moura 2001), the concentration of U-46619
was titrated within a range of 0.01–0.03 μM to achieve a
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comparable contraction level for each group when compared
to the respective control group. When a stable level of tone
was maintained (after about 45 min exposure time), the
vasorelaxant effects of the agonists were examined.
Rosiglitazone was given in two ways. In the first series, only
one concentration of the agonist (0.1, 1, 10, and 100 μM) was
administered in one arterial preparation in order to examine its
time-dependent effect, and the relaxant influence of agonist
was observed over 120 min. To assess the contribution of
PPARγ activation, some experiments were performed in
the presence of the PPARγ antagonist GW9662 (1 or
10 μM; O’Sullivan et al. 2005, 2006) added 10 min prior
to precontraction (O’Sullivan et al. 2005). In the second
series, cumulative concentration–response curves (CRCs)
for rosiglitazone and pioglitazone (0.01–100 μM) or the
prostacyclin (IP) receptor agonist iloprost (0.001–10 μM)
were constructed by cumulative addition of agonists in
order to examine their vasodilatory effects. In order to
examine the mechanism(s) involved in the vasodilatory
effect of the agonists, rings were exposed from 30 min
prior to precontraction of arteries until the end of the
experiments with the following inhibitors (the respective
receptors, enzymes, or ion channels are given in brackets):
RO1138452 1 and 10 μM (prostacyclin IP receptors;
Jones et al. 2006), NG-nitro-L-arginine methyl ester (L-
NAME) 300 μM (nitric oxide synthase; Kozłowska et al.
2007), indomethacin 10 μM (cyclooxygenase, COX;
Kozłowska et al. 2007), and glibenclamide 10 μM
(KATP; Irat et al. 2006). In control tissues of both series,
the respective vehicle of agonists or antagonists was used
instead. In each individual preparation, only one experimental
curve was determined. All experiments were performed in
paired vessels, i.e., the effect of a drug or of endothelium
denudation was studied in one vessel, whereas another vessel
from the same patient served as control.
In order to examine whether rosiglitazone is a direct antag-
onist at the thromboxane receptor, some rings were treated for
30 min with one concentration (10 μM) of rosiglitazone or its
vehicle (DMSO 0.01 %v/v; controls) and then the CRC for U-
46619 (0.001–3 μM) was constructed.
Drugs used
(−)-Phenylephrine hydrochloride, acetylcholine chloride, and
L-NAME (Sigma, Munich, Germany) were dissolved in de-
ionized water, whereas indomethacin (Sigma, Munich,
Germany) was dissolved in 0.5 M NaHCO3. Iloprost
(Schering AG, Berlin, Germany) was dissolved in 0.9 %
NaCl. U-46619 (9,11-dideoxy-9α,11α-methanoepoxy prosta-
glandin F2α) (Cayman Chemicals, Ann Arbor, MI, USA) was
supplied in 100 % ethanol and further diluted with deionized
water to the concentration required. Rosiglitazone (Cayman
Chemicals) and pioglitazone hydrochloride (Biotrend, Köln,
Germany) were supplied in DMSO and further diluted with
deionized water to the concentration required. Stock solutions
of glibenclamide (in DMSO) and RO1138452 (4,5-dihydro-
N-[[4-(1-methylethoxy)phenyl)]-1H-imidazol-2-amine, CAY-
10441) (Cayman Chemicals) (in ethanol) were diluted with
water such that the final concentration of the organic solvent
in the organ bath was less than 0.01 %v/v.
Calculations and statistical analysis
The relaxation elicited by rosiglitazone, pioglitazone, and
iloprost or their solvents was expressed as percentage of the
precontraction induced by U-46619. EC50 values were used
to determine the potency of U-46619 as a contractile agent
and of rosiglitazone and iloprost as vasodilators. For U-
46619, the EC50 is the concentration causing the half-
maximum effect, and for rosiglitazone and iloprost, the
EC50 is the concentration causing a relaxation of 50 % of
the precontracted vessel. Note that for rosiglitazone, EC50
values could be obtained only for those experiments in
which one concentration was given per vessel, since in the
experiments with cumulative administration, plateaus of the
vasodilatory effect were not reached when the next higher
drug concentrations were given. The antagonistic potency
(pA2) of RO1138452 against iloprost was calculated from
the equation pA2=−log[B]+log (r−1), where [B] is the
molar concentration of RO1138452 and r is the concentra-
tion ratio of the EC50 values of iloprost in the presence and
absence of RO1138452. In order to assess the potency of
endothelial denudation and of various antagonists and in-
hibitors in those experiments in which rosiglitazone was
given cumulatively, the rightward shift was determined on
the basis of the EC25 values, i.e., those values leading to a
vasodilation of 25 % of the precontracted vessel.
Results are expressed as mean±SEM of n experiments
from three different patients (data from Figs. 1 and 5b) and
from at least four different patients (rest). Statistical analyses
were performed using t test for unpaired data. When two or
more treatment groups were compared to the same control, the
one-way analysis of variance followed by the Dunnett test was
used (Prism 5, GraphPad Software Inc., La Jolla, CA, USA).
Differences were considered as significant when P<0.05.
Results
General
The vasodilatory effect of rosiglitazone was studied under
various experimental conditions. The thromboxane A2 receptor
agonist U-46619 was used to precontract the hPA. U-46619
(0.001–3 μM) induced a virtually identical concentration-
dependent contraction in the absence (pEC50=7.54 ± 0.04,
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n=3) and in the presence of rosiglitazone (10 μM; pEC50=
7.43±0.06, n=3) (Fig. 1). Rosiglitazone did not modify the
basal tone by itself (not shown). In the subsequent experi-
ments, the vascular rings were first preconstricted with U-
46619 at a concentration approximately equivalent to its EC60.
In preparatory experiments, the U-46619-induced con-
traction was not affected by GW9662 (1 and 10 μM),
RO1138452 (1 and 10 μM), and endothelial denudation
but slightly increased by L-NAME (300 μM), indomethacin
(10 μM), and glibenclamide (10 μM) (not shown). To adjust
the degree of the U-46619-induced contraction to the level
in controls, lower concentrations of U-46619 were used in
the presence of the latter three inhibitors (for details, see
“Material and methods”). In this way, the tension, which
amounted to 8.92±0.98 in 17 controls, did not differ between
the various experimental groups (not shown).
Vasodilatory effects of PPARγ agonists
As shown in Fig. 2a, pioglitazone and rosiglitazone (0.01–
100 μM each) given cumulatively caused a concentration-
dependent full relaxation of the endothelium-intact hPAs
preconstricted with U-46619. The first vasodilatory effect of
pioglitazone and rosiglitazone (by about 20 %) was induced
by 3 and 1 μM, respectively, and occurred about 25–30 min
after the administration of the lowest concentration of the
agonist. The time necessary to reach full vasorelaxation was
100.9±6.4 (n=8) and 102.3±7.2 min (n=17), respectively.
Rosiglitazone exhibited a slightly greater potency than
pioglitazone (by a factor of 2.1). Thus, in all further studies,
we examined the vasodilatory effect of rosiglitazone only.
Rosiglitazone, given in single concentrations, (but not its
vehicle) caused not only a concentration- but also time-
dependent relaxation of the endothelium-intact hPAs
preconstricted with U-46619 (Figs. 2 and 3). The shape of
the time–effect curves suggests that the maximal relaxation
obtainable with each of the four concentrations of rosiglitazone
occurs after about 120 min. A virtually full relaxation was
obtained with the highest concentration of rosiglitazone. The
pEC50 value was 5.55 (n=6–10; points for particular
Fig. 2 Concentration–response curves (a) and representative original
traces (b, c) of the rosiglitazone- and/or pioglitazone-induced relaxa-
tion of endothelium-intact isolated human pulmonary arteries. A cu-
mulative concentration–response curve was constructed [pioglitazone
(a) or rosiglitazone (a, c)] or single concentrations of rosiglitazone
were given (a, b; exposure time 120 min). Arrows (b, c) show the
moment of application of the particular concentrations of rosiglitazone.
Broken arrows (c) represent the following concentrations (from the
left): 0.03, 0.3, 3, and 30 μM, respectively. Results in a are expressed
as percentage relaxation of the isometric contraction induced by U-
46619. Mean±SEM of 5–17 tissues for each curve
Fig. 1 Influence of rosiglitazone on the concentration-dependent
vasocontraction induced by U-46619 in endothelium-intact human
pulmonary arteries. Results are expressed as percentage of maximal
(max.) contraction. Mean±SEM of three arteries for each curve. In
many cases, SEM is smaller than or equal to the size of symbols
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concentrations were obtained from different patients, and for
this reason, an SEM value could not be determined). A com-
parison of the CRCs for rosiglitazone given cumulatively and
separately shows that they are very similar (Fig. 2a).
Involvement of PPARγ receptors in the vasodilatory effect
of rosiglitazone
The PPARγ antagonist GW9662 (1 and 10 μM) reduced the
time-dependent relaxation induced by rosiglitazone (10 μM;
approximately equivalent to its EC70) in a concentration-
dependent manner. The attenuation became significant after
60 and 30 min, and the maximal effects (at 120 min) were
diminished by about 35 and 80 %, respectively (Fig. 3b).
Involvement of NO, cyclooxygenase product(s), and KATP
channels in the vasodilatory effect of rosiglitazone
The CRC for rosiglitazone (given cumulatively) was shifted to
the right by removal of the endothelium, the cyclooxygenase
inhibitor indomethacin (10 μM), and the inhibitor of NO
synthesis, L-NAME (300 μM), by factors of 10, 13, and 10,
respectively. Under each condition, the relaxation obtained
with the highest agonist concentration was diminished by
about 50 % (Fig. 4a, b). The KATP channel antagonist
glibenclamide (10 μM) diminished the rosiglitazone
(100 μM)-induced relaxation by about 70 % and shifted its
CRC to the right by a factor of 35 (Fig. 4a). The vehicle for
glibenclamide (DMSO 0.01 %v/v) did not modify the CRC
for rosiglitazone (not shown).
Involvement of IP receptors in the vasodilatory effect
of rosiglitazone
The prostacyclin IP receptor antagonist RO1138452 (1 and
10 μM) reduced the rosiglitazone (100 μM)-induced
Fig. 3 Time-dependent vasorelaxation induced by single concentra-
tions of rosiglitazone (a) and its interaction with the PPARγ receptor
antagonist GW9662 (b) in the human endothelium-intact pulmonary
artery. Results are expressed as percentage relaxation of the isometric
contraction induced by U-46619. Mean±SEM of five to ten tissues for
each curve. *P<0.05, **P<0.01, ***P<0.001 compared to rosiglitazone
alone
Fig. 4 Influence of endothelium removal, of the KATP channel blocker
glibenclamide (a), the NO synthesis inhibitor NG-nitro-L-arginine
methyl ester (L-NAME), and the cyclooxygenase inhibitor indometh-
acin (Indo) (b) on the concentration-dependent vasorelaxation induced
by rosiglitazone in human pulmonary arteries. Results are expressed as
percentage relaxation of the isometric contraction induced by U-46619.
In a, the effect of the vehicle for rosiglitazone (DMSO 0.01 %v/v each)
is shown as well. Mean±SEM of 7–17 tissues for each curve
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vasodilation by about 50 and 85 %, respectively (Fig. 5a).
The lower concentration of RO1138452 shifted the CRC for
rosiglitazone to the right by a factor of 13 (Fig. 5a).
In additional experiments, the interaction of RO1138452
with the stable analogue of prostacyclin, iloprost, was studied
as well (Fig. 5b). Iloprost (0.001–10 μM) caused a full relax-
ation of the endothelium-intact hPA preconstricted with U-
46619. Although the lower part of the CRC may suggest a
biphasic effect, evaluation with a computer-based fitting pro-
gram revealed that a monotonic curve is statistically preferred.
RO1138452 (1 μM) attenuated the iloprost (10 μM) relaxa-
tion by 30 % and shifted the CRC for iloprost to the right by a
factor of 14. Since for iloprost (as opposed to rosiglitazone)
the vasodilator effects upon cumulative administration
plateaued within short time periods, pEC50 and apparent pA2
values could be determined. The pEC50 for iloprost (in the
absence of RO1138452) is 6.47±0.22 and the apparent pA2 of
RO1138452 (1 μM) against iloprost is 7.21.
Discussion
The aim of the present study was to examine whether
PPARγ agonists influence the contractile tone of the human
pulmonary artery and we could show for the first time that
both rosiglitazone and pioglitazone relax this vessel. In
addition, the potential mechanisms involved in the vasodi-
lator effect of rosiglitazone were studied. For the experi-
ments, we used the thromboxane analogue U-46619 as the
contractile agent since thromboxane A2 plays a major role as
a vasoconstrictor in the pulmonary circulation and may be
involved in the pathogenesis of pulmonary hypertension (for
review, see Sutliff et al. 2010; Archer et al. 2010; Green et
al. 2011). In addition, U-46619 was also used in most other
studies in which vasodilator effects of PPARγ agonists were
examined (see below). The possibility had to be considered
that the vasorelaxant effect of rosiglitazone in our model,
like in mouse mesenteric arteries (Yuen et al. 2011), is
related to a direct antagonistic effect at thromboxane (TP)
receptors, but rosiglitazone 10 μM (i.e., at a concentration
which relaxes the hPA preconstricted with U-46619 by 60–
70 %) did not modify the U-46619-induced vasoconstriction
in pulmonary arteries without preconstriction. Similarly,
both pioglitazone and rosiglitazone did not change the con-
traction induced by U-46619 in rat mesenteric arteries
(Mendizábal et al. 2011).
The vasorelaxant effect of PPARγ agonists
Cumulative application of pioglitazone and rosiglitazone
caused a concentration-dependent and full relaxation of the
endothelium-intact hPAs preconstricted with U-46619.
Rosiglitazone proved to be more potent than pioglitazone
and the same rank order of potency was also noticed in
binding studies to human PPARγ (Fujimura et al. 2006).
So, we preferred rosiglitazone as reference PPAR agonist in
all further experiments. Importantly, the clinically effective
pioglitazone and rosiglitazone blood concentrations of about
0.83–1.82 (Omae et al. 2011) and 0.6–1 μM (Irat et al.
2006), respectively, are contained in the concentration range
studied on hPAs in the present investigation. Unlike in
hPAs, the maximal vasodilatory effect of rosiglitazone in
isolated animal arteries was less than 100 %, namely 45, 40,
and 60 % in the mouse pulmonary artery, aorta, and carotid
artery, respectively (Ryan et al. 2004; Harrington et al.
2010), 30 % in the rat aorta (Nomura et al. 2008) and
50 % in the porcine retinal artery (Omae et al. 2011). As
opposed to the vessels mentioned above, rosiglitazone
caused vasoconstriction in human small arteries isolated
from subcutaneous fat (Walker et al. 1998).
Rosiglitazone produced a slowly (over 120 min) rather
than an acutely developing relaxation of the rat aorta
preconstricted with methoxamine (Cunnane et al. 2004) or
Fig. 5 Influence of the prostacyclin IP receptor antagonist RO1138452
on the concentration-dependent vasorelaxation induced by rosiglitazone
(a) and iloprost (b) in human endothelium-intact pulmonary arteries.
Results are expressed as percentage relaxation of the isometric contrac-
tion induced by U-46619. Mean±SEM of three to seven tissues for each
curve
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U-46619 (O’Sullivan et al. 2005). Thus, in additional exper-
iments, we registered the vasodilatory influence of single
concentrations of rosiglitazone given separately over 2 h.
Again, the PPARγ agonist produced a concentration- and
time-dependent, slowly developing decrease in tone of the
isolated endothelium-intact hPAs preconstricted with U-
46619. Interestingly, the CRCs for rosiglitazone given sepa-
rately and cumulatively were very similar, and in both cases,
full relaxation was noticed. It was induced by 100 μM and
was reached after 120 min (administration of a single concen-
tration) and 110 min of incubation (cumulative CRC). The
time–effect curve for rosiglitazone 10 μM on the hPA is very
similar to that in the rat aorta preconstricted also with U-46619
(O’Sullivan et al. 2005). Thus, in both cases, the first
vasodilatory response (by about 15–20 %) occurred after
15 min and maximal relaxation by about 70 % after 120 min.
Mechanisms involved in the rosiglitazone-induced
relaxation
Does the vasorelaxant effect of rosiglitazone involve PPARγ
receptors? In order to finally examine this point, we examined
the influence of GW9662, a potent and selective antagonist of
these receptors (Michalik et al. 2006). As a matter of fact,
GW9662 1 and 10 μM diminished the rosiglitazone (10 μM)-
induced relaxation in hPA after 120 min of incubation by
about 35 and 80 %, respectively. In good agreement with
our own data, GW9662 1 μM attenuated the rosiglitazone
(10 μM)-induced vasorelaxation of the isolated rat aorta after
120 min by about 40 % (O’Sullivan et al. 2005). According to
O’Sullivan et al. (2005, 2006), the slow relaxation induced by
rosiglitazone is related to the fact that the activation of intra-
cellular PPARγ receptors leads to the transcription of respon-
sive genes.
In further experiments, we demonstrated that endotheli-
um removal reduced the vasorelaxant effect of rosiglitazone
in the hPA by about 50 %. Thus, the vasodilatory action of
rosiglitazone consists of an endothelium-dependent and
endothelium-independent component. Similarly, removal
of the endothelium counteracted the vasodilatory effect
of rosiglitazone in the rat aorta (Cunnane et al. 2004).
Rosiglitazone has also been shown to increase the
endothelium-dependent flow in the brachial artery of a
healthy man after 6 h (Walcher et al. 2010). Since we were
interested in the endothelium-dependent vasodilatory compo-
nent of rosiglitazone, all further experiments were performed
in endothelium-intact vessels.
First, we have checked whether the effect of rosiglitazone
might be related to nitric oxide, one of the main endothelial
vasodilators. L-NAME, an inhibitor of the biosynthesis of
nitric oxide by endothelial cells, attenuated the vasodilatory
effect of rosiglitazone, suggesting that nitric oxide plays a role
in its effect. Similarly, L-NAME diminished the rosiglitazone-
induced relaxation of the rat aorta (Cunnane et al. 2004). In
studies from the literature on cultured endothelial cells, both
PPARγ-dependent and PPARγ-independent mechanisms of
rosiglitazone have been identified. Thus, the rosiglitazone-
induced NO synthesis and/or endothelial nitric oxide synthase
(eNOS) stimulation was not modified by GW9662 in human
aortic (Boyle et al. 2008) but inhibited in porcine iliac artery
(Zhao et al. 2011) and completely abolished in human umbilical
vein (Polikandriotis et al. 2005) endothelial cells.
Second, a possible role of cyclooxygenase products in the
effect of rosiglitazone had to be taken into account. It has been
suggested that a combination of prostacyclin analogues and
PPARγ receptor agonists may be effective to counteract ab-
normal vascular remodeling in PAH (for review, see, e.g.,
Green et al. 2011) since antiproliferative responses to prosta-
cyclin analogues were potentiated by rosiglitazone in periph-
eral pulmonary arterial smooth muscle cells from patients
suffering from idiopathic PAH (Falcetti et al. 2010). We found
that the rosiglitazone-induced vasorelaxation of hPA was at-
tenuated by indomethacin, an inhibitor of COX. Moreover,
the selective prostacyclin IP receptor antagonist RO1138452
inhibited the rosiglitazone-evoked vasorelaxation of the hPA
and showed the same extent of rightward shift as in the case of
the CRC of iloprost. Thus, our data suggest that rosiglitazone
may increase the formation of vasorelaxant prostacyclin (or
another vasorelaxant product of COX activity).
Third, the insulin sensitizer rosiglitazone has been shown
to restore, via ATP-sensitive K+ (KATP) channels, the vaso-
relaxation of human omental arteries impaired by high glu-
cose (Kinoshita et al. 2006). In addition, it has been recently
suggested that opening of KATP channels activates eNOS in
order to generate NO and thus regulates vasorelaxation
(Grossini et al. 2009). Thus, we checked whether KATP
channels are involved in the vasodilatory effect of
rosiglitazone. Indeed, the vasodilator effect of rosiglitazone
was markedly attenuated by glibenclamide, a selective
blocker of ATP-activated K+ channels. However, one should
keep in mind that in contrast to our results and those
obtained by Kinoshita et al. (2006), rosiglitazone, acting
via vascular KATP channels, inhibited the isoprenaline-
induced coronary vasodilatation in mice (Yu et al. 2011).
Study limitations
As already mentioned above, rosiglitazone showed slow ki-
netics in human pulmonary arteries. Therefore, it was difficult
to reach a plateau for each agonist concentration when the
cumulative technique was applied. Nevertheless, since cumu-
lative concentration–response curves to rosiglitazone were
established both in the absence and in the presence of in-
hibitors, the rightward shifts of the curves reflect the blocking
effect of the inhibitors. Moreover, one should keep in mind
that our patients did not have any clinical evidence of
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pulmonary hypertension. Thus, pulmonary vessels in the
present study might be more responsive to PPARγ ago-
nists than those from patients with PAH (for literature, see
“Introduction”). Thus, the presently reported effects may
represent an overestimation of their potential use.
Pulmonary arterial hypertension—a new indication
for a “difficult” class of drugs?
Our data demonstrating that pioglitazone and rosiglitazone
induce a full relaxation of hPAs lend further support to the
suggestion made by others (for literature, see “Introduction”)
that PPARγ agonists may become useful adjuncts to current
therapies for pulmonary hypertension. Importantly, one should
keep in mind that, in addition to vasodilatation, PPARγ ago-
nists have beneficial effects on remodeling of pulmonary blood
vessels and lung morphology. Thus, chronic treatment with
rosiglitazone and/or pioglitazone prevented and/or reversed
pulmonary vascular remodeling, neomuscularization, and/or
right ventricular hypertrophy induced by monocrotaline
(Matsuda et al. 2005) or hypoxia in rats (Crossno et al. 2007;
Kim et al. 2010) and in adult (but not in newborn) mice (Nisbet
et al. 2010; Nicola et al. 2011). Rosiglitazone also attenuated
the proliferation of human pulmonary artery endothelial cells
(Kang et al. 2011) and rat pulmonary artery smooth muscle
cells (Li et al. 2010) stimulated by hypoxia or serotonin,
respectively. An indirect piece of evidence for the suitability
of PPARγ agonists in the treatment of PAH is the fact that
targeted deletion of PPARγ, in mice smooth muscle
(Hansmann et al. 2007) and endothelial cells (Guignabert et
al. 2009), results in muscularization of small distal pulmonary
arteries and the development of PAH and that, following
cessation of hypoxia, PAH persists longer in mice with endo-
thelial PPARγ deletion (Guignabert et al. 2009).
The use of rosiglitazone and pioglitazone, which are indi-
cated for the treatment of type 2 diabetes mellitus (for review,
see Michalik et al. 2006; Ciudin et al. 2012), has been restrict-
ed or become questionable due to the occurrence of severe
side effects (Palee et al. 2011; Ciudin et al. 2012). It is unclear
whether the problems associated with the use of the two
thiazolidinediones are class effects or are related to particular
properties of the single compounds (Ciudin et al. 2012). A
new class of drugs, termed selective PPARγ modulators,
which show attenuated cardiovascular side effects and are
being developed currently, may become alternative drugs for
the treatment of type 2 diabetes (Ciudin et al. 2012) and
perhaps also of pulmonary arterial hypertension.
Conclusions
Rosiglitazone and pioglitazone cause a full relaxation of the
isolated human pulmonary artery. The rosiglitazone-induced
effect occurs with a delay, involves PPARγ receptors,
and is partially dependent on vascular endothelium.
Moreover, it results from (1) the stimulation of NO
release from endothelial cells, (2) the activation of IP
receptors through production of prostacyclin, and (3) the
stimulation of vasodilatory ATP-sensitive K+ channels.
Thus, the ability of these thiazolidinediones to relax
hPAs is a further piece of evidence that PPARγ agonism
may represent a new strategy for the treatment of pul-
monary hypertension.
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